Prime Medicine wins arbitration with Beam over AATD therapy PM647

Prime Medicine won a binding arbitration against Beam Therapeutics regarding their 2019 collaboration agreement. The tribunal ruled that the AATD therapy PM647 falls within Prime Medicine's licensed field, finding no breach by Prime Medicine. Consequently, no monetary damages were awarded to Beam. Prime Medicine plans to file for an IND/CTA for PM647 in Q3 2026, with initial clinical data expected in 2027.

Prime Medicine won a binding arbitration with Beam Therapeutics under their 2019 collaboration and license agreement. * The tribunal ruled PM647 falls within Prime Medicine’s licensed “Field,” finding no breach tied to its AATD program. * No monetary damages were awarded to Beam. * Prime Medicine targets an IND and/or CTA filing for PM647 in Q3 2026; initial clinical data expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080800PRIMZONEFULLFEED9758777) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)